In short: Named alongside AbbVie and AstraZeneca as Lebenthal's preference over Lilly (39:35) — a more diversified drug maker.
In short: Call of the day — reinstated overweight at Morgan Stanley, $665 target, and owned by Jim Lebenthal. His case is franchise plus pipeline: "this is a company with terrific science. It pretty much owns the cystic fibrosis business, but they've added to it with things like kidney treatments and pain treatments. They have great science. They are likely to put out more products like that." The caveats are stated in the same breath — "a little bit expensive. There can always be a hiccup along the way" — but "the momentum, Joe, is clearly here in this name." Terranova adds the corporate action: "excellent deal on Monday — a $10 billion acquisition, diversifies beyond cystic fibrosis. Not that they need to, they dominate there, but this is a good deal." (The auto-transcript garbles the target's name as "Chronetics Pharmaceutical"; the real name is not recoverable from the audio and is not asserted here.)
Vertex owns the treatment of cystic fibrosis almost outright — a genetic lung disease with a small patient population but essentially no competing therapy, which is why the business throws off dependable cash. Morgan Stanley reinstated coverage at overweight with a $665 target.
The whole investment question for a company like this is what happens after the one franchise. Lebenthal's answer is that the science travels: they have moved into kidney disease and, more importantly, non-opioid pain treatment, which is a vastly larger market than cystic fibrosis. Terranova adds the other route — the $10 billion acquisition announced Monday, which buys diversification rather than waiting for the labs to produce it.
Note what he is careful to say: they are not buying because they have to. A company forced into deals by a decaying core is a different (and worse) proposition from one buying from strength. Lebenthal's caveats are the honest ones — it is not cheap, and single-product biotech always carries the risk of one bad trial headline.
In short: Named by Wapner as one of Raskin's healthcare holdings ("Amy has Illumina, Amy has Vertex, among others"), and she answers with the sector view rather than the single name: "I think the healthcare trade has more legs to run" — on personalized medicine arriving and a genomics/biotech complex whose market caps remain small relative to the AI-infrastructure names. No separate argument on Vertex itself this episode.
Vertex is best known for treatments for cystic fibrosis and is one of Amy Raskin's healthcare positions, named by Wapner alongside Illumina.
She does not argue the individual name this episode; she answers with the sector view — "the healthcare trade has more legs to run" — and then spends her time on Illumina. The underlying case is the same one she makes throughout: genomics and personalised medicine are arriving as real commercial businesses, and the companies serving that shift are still small compared with the AI-infrastructure names now worth hundreds of billions.
In short: Final trade. "A great healthcare name" — biopharma with its cystic-fibrosis franchise plus "other shots on goal." Fits his broader call that healthcare, "left for dead six months ago," has come alive as the hot sector.
Vertex is a biotech whose cash machine is its cystic-fibrosis drug franchise — it essentially dominates treatment for that disease, giving it durable, high-margin revenue. Lebenthal's "other shots on goal" means the company has additional drugs in development (in areas like pain and kidney disease) that could each add a new growth leg if they succeed.
He picked it as his final trade to express a broader view: healthcare was "left for dead six months ago" and is now "the hot sector," so he wants a high-quality name to ride that comeback — and Vertex, with a protected core business plus optionality, fits.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.